PT-141

PT-141 (Bremelanotide) is a cyclic heptapeptide that acts as a melanocortin receptor agonist, with particular affinity for the MC3 and MC4 receptor subtypes. It was originally developed from the linear alpha-melanocyte-stimulating hormone (alpha-MSH) peptide Melanotan II, with structural modifications that enhance its selectivity for central nervous system melanocortin receptors.

Unlike compounds that act on peripheral vascular mechanisms, PT-141 works through direct activation of CNS melanocortin pathways, making it a unique tool for researchers studying the neurological basis of sexual function and arousal. This central mechanism of action has made it one of the most interesting peptides in neuroendocrine research.

PT-141's cyclic structure confers enhanced enzymatic stability compared to linear peptide analogs, and its melanocortin receptor selectivity profile provides researchers with a relatively targeted tool for investigating MC3R/MC4R-mediated signaling pathways.

The compound has been extensively studied in both animal models and clinical research settings, contributing significantly to our understanding of melanocortin system involvement in sexual function, energy balance, and social behavior.